In South Africa, Success Against H.I.V. Offers Hope
A former Africa correspondent, who covered the height of the AIDS epidemic there 15 years ago, finds lessons in the remarkable progress against that virus for our current fight.
Category: Acquired Immune Deficiency Syndrome
A former Africa correspondent, who covered the height of the AIDS epidemic there 15 years ago, finds lessons in the remarkable progress against that virus for our current fight.
A former Africa correspondent, who covered the height of the AIDS epidemic there 15 years ago, finds lessons in the remarkable progress against that virus for our current fight.
A former Africa correspondent, who covered the height of the AIDS epidemic there 15 years ago, finds lessons in the remarkable progress against that virus for our current fight.
A former Africa correspondent, who covered the height of the AIDS epidemic there 15 years ago, finds lessons in the remarkable progress against that virus for our current fight.
Scientists in a cutting-edge laboratory do part of the work. Local health workers on foot do the rest.
In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. by 2021. That preceded an ambitious global campaign to curb the virus. How well did it work?
In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. by 2021. That preceded an ambitious global campaign to curb the virus. How well did it work?
In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. by 2021. That preceded an ambitious global campaign to curb the virus. How well did it work?
Researchers ended a large trial in South Africa after finding that an experimental vaccine offered little protection.
Researchers ended a large trial in South Africa after finding that an experimental vaccine offered little protection.
Even with U.N.’s previous goals unmet, delegates tried to water down provisions regarding protections for vulnerable populations and patents for essential drugs.
Even with U.N.’s previous goals unmet, delegates tried to water down provisions regarding protections for vulnerable populations and patents for essential drugs.
A chemist by training, he turned Gilead Sciences into a leading, and lucrative, innovator with single-pill treatments for H.I.V. and hepatitis C.
A chemist by training, he turned Gilead Sciences into a leading, and lucrative, innovator with single-pill treatments for H.I.V. and hepatitis C.
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
Two decades ago, the U.S. launched a program to help supply the world with H.I.V. medication. It should take a similar approach to Covid.
Two decades ago, the U.S. launched a program to help supply the world with H.I.V. medication. It should take a similar approach to Covid.
Two decades ago, the U.S. launched a program to help supply the world with H.I.V. medication. It should take a similar approach to Covid.
Two decades ago, the U.S. launched a program to help supply the world with H.I.V. medication. It should take a similar approach to Covid.
Two decades ago, the U.S. launched a program to help supply the world with H.I.V. medication. It should take a similar approach to Covid.
Two decades ago, the U.S. launched a program to help supply the world with H.I.V. medication. It should take a similar approach to Covid.
For the 80,000 children who die of H.I.V. each year, drugs are often bitter or hard to swallow. Dolutegravir will soon come in a tasty dissolving tablet.